Women's Health Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Docetaxel

Alternative docetaxel administration schedule evaluated

According to recent research from the Netherlands, "The anti-cancer agent docetaxel is approved for the treatment of patients with locally advanced or metastatic breast cancer, non-small cell lung cancer (NSCLC) and for the treatment of androgen-independent prostate cancer. At the recommended dose of 60-100 mg/m² given every 3 weeks, severe neutropenia is the dose-limiting toxicity and a major concern especially when treating patients at high-risk from myelotoxic complications."

"A less toxic schedule, involving weekly docetaxel administration was developed for...

• View Other Issues of Women's Health Weekly
  
• View Other NewsRx Publications